Autologous CD34+ cell transduced with retroviral vector that encodes for the human adenosine deaminase (ADA) cDNA sequence

N/A

Report date: 2023/01/12 15:52:21

Base Information

Drug NameAutologous CD34+ cell transduced with retroviral vector that encodes for the human adenosine deaminase (ADA) cDNA sequence

Drug Alias NameStrimvelisGSK-2696273

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapyCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Retroviral vector

Mechanisms of ActionADA gene transference

TargetsAdenosine deaminase

Therapy Area/IndicationsSevere Combined Immunodeficiency

Global Approved IndicationsSevere Combined Immunodeficiency

Approved Indications in ChinaN/A

Original Approved Country/TerritoryEU

Original Approved Date2016/05/26

Country/TerritoryEU

CombinationsNo

Global Highest StatusApproved

Highest Status in ChinaN/A

Originator CompaniesOspedale San Raffaele University Of Siena Fondazione Telethon

China Registration ClassN/A

Develop Information

Active CompaniesFondazione Telethon ETS Orchard Therapeutics Plc

Inactive CompaniesN/A

Active IndicationsSevere Combined Immunodeficiency

Inactive IndicationsN/A

Other Information

ATC CodeL03A